Showing 8361-8370 of 8687 results for "".
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- AD RescueWear Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/20121204-ad_rescuewear_receives_nea_seal_of_acceptance/2459662/The National Eczema Association Seal of Acceptance was awarded to AD RescueWear for its use by patients with eczema or severe sensitive skin conditions. AD RescueWear manufactures and sells ready-made, wet wrap therapy products for the treatment
- ARTAS System Adopted by Minneapolis Surgeonhttps://practicaldermatology.com/news/20121204-artas_system_adopted_by_minneapolis_surgeon/2459664/Restoration Robotics, Inc. announced the first use of its revolutionary ARTAS System in Minneapolis by Dr. Ron Shapiro of Shapiro Medical Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technolo
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast c
- Eccrine Sweat Glands' Role in Wound Healing Revealedhttps://practicaldermatology.com/news/20121121-eccrine_sweat_glands_role_in_wound_healing_revealed/2459675/Human eccrine sweat glands store a reservoir of adult stem cells that may be recruited to aid wound healing, a new report suggests. According to University of Michigan researchers behind the study (Am J Pathol. E-pub), sweat glands appear to play a pivotal role in wound healing. For the study, part
- Valeant Receives FTC Clearance For Medicis Acquisitionhttps://practicaldermatology.com/news/20121121-valeant_receives_ftc_clearance_for_medicis_acquisition/2459676/The US Federal Trade Commission (FTC) granted early termination of the waiting period surrounding the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant Pharmaceuticals International, Inc., effective November 15, 2012. The propo